Tarsus Pharmaceuticals (TARS) Cash from Investing Activities (2019 - 2026)

Tarsus Pharmaceuticals' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at -$58.6 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 67.6% year-over-year to -$58.6 million in Q1 2026; TTM through Mar 2026 was -$65.7 million, a 50.17% increase from a year earlier, with the FY2025 full-year figure at -$42.1 million, up 78.86% from the prior year.
• Cash from Investing Activities fell to -$58.6 million in Q1 2026 per TARS's latest filing, from $49.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $64.1 million in Q2 2023 and bottomed at -$102.2 million in Q1 2024.
• The 5-year median for Cash from Investing Activities is -$4.7 million (2025), against an average of -$17.9 million.
• Across the five-year window, Cash from Investing Activities tumbled 47112.4% in 2022 and surged 52634.43% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at -$87.2 million in 2022, then jumped by 120.47% to $17.8 million in 2023, then plunged by 433.75% to -$59.6 million in 2024, then jumped by 182.71% to $49.3 million in 2025, then sank by 218.85% to -$58.6 million in 2026.
• Per Business Quant, the three latest TARS Cash from Investing Activities figures stand at -$58.6 million (Q1 2026), $49.3 million (Q4 2025), and -$4.7 million (Q3 2025).